[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335767-105":59,"doc-detail-335767-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","histopathologic-features-and-transcriptomic-signatures-do-not-solve-the-issue-of-magnetic-resonance-imaging-invisible-prostate-cancers-a-matched-pair-analysis","Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging‐Invisible Prostate Cancers - A Matched-Pair Analysis","","Multiparametric magnetic resonance imaging (mpMRI) is central to prostate cancer diagnosis, yet some clinically significant cancers remain undetected. This retrospective matched-pair analysis investigates the pathological and molecular basis of visibility at mpMRI by comparing mpMRI-invisible versus mpMRI-visible clinically significant prostate cancers confirmed after radical prostatectomy. Patients with negative preoperative mpMRI were matched by age, PSA, prostate volume, and ISUP grade group, followed by histopathologic review and mRNA profiling. No overall pathological or gene-expression hallmarks explained mpMRI invisibility, though aggressive molecular programs emerged in defined subgroups.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/histopathologic-features-and-transcriptomic-signatures-do-not-solve-the-issue-of-magnetic-resonance-imaging-invisible-prostate-cancers-a-matched-pair-analysis/335767/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/histopathologic-features-and-transcriptomic-signatures-do-not-solve-the-issue-of-magnetic-resonance-imaging-invisible-prostate-cancers-a-matched-pair-analysis/335767.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does this study address regarding mpMRI in prostate cancer?","Question",{"text":112,"@type":113},"Some clinically significant prostate cancers remain invisible on multiparametric MRI despite good performance. The study examines why these mpMRI-invisible cancers can be missed.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients selected and compared in this matched-pair analysis?",{"text":117,"@type":113},"Men with clinically significant prostate cancer undergoing radical prostatectomy (ISUP grade group ≥ 2) from 2015 to 2020 were included. A cohort with negative preoperative mpMRI was matched to an mpMRI-visible cohort based on age, PSA, prostate volume, and ISUP grade group.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings about histopathology and gene-expression profiles?",{"text":121,"@type":113},"Overall, no significant differences in histopathologic features, tumor diameter and location, mRNA expression profile, pathways, or cell-type scores were found between matched cohorts. In stratified analyses, specific subgroups of mpMRI-invisible cancers showed upregulation of cell adhesion, motility, extracellular matrix remodeling, and metastatic-process pathways.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335767,1790621240,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","The Prostate  \nORIGINAL ARTICLE   \nHistopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging‐Invisible Prostate Cancers: A Matched‐Pair Analysis  \nMarco Oderda1  | Alessandro Marquis1  | Luca Bertero2 | Giorgio Calleris1 | Riccardo Faletti3 | Marco Gatti3 |  \nLuca Mangherini2 | Giulia Orlando4 | Giancarlo Marra1 | Irene Ruggirello2 | Elena Vissio2 | Paola Cassoni2 | Paolo Gontero1  \n1Department of Surgical Sciences, Division of Urology, Molinette Hospital, University of Turin, Turin, Italy | 2Department of Medical Sciences, Division of Pathology, Molinette Hospital, University of Turin, Turin, Italy | 3Department of Surgical Sciences, Division of Radiology, Molinette Hospital, University of  \nTurin, Turin, Italy | 4Department of Oncology, Division of Pathology, Molinette Hospital, University of Turin, Turin, Italy Correspondence: Marco Oderda (marco.oderda@unito.it)  \nReceived: 8 April 2024 | Revised: 24 November 2024 | Accepted: 2 December 2024  \nFunding: The present project was supported by a grant of “Rete Oncologica Piemonte e Valle d'Aosta.”  \nKeywords: diagnostic imaging | expression profiling | genomic | MRI invisible | nanostring | prostate cancer (clinically significant)  \nABSTRACT  \nBackground: Multiparametric magnetic resonance imaging (mpMRI) is pivotal in prostate cancer (PCa) diagnosis, but some clinically significant (cs) PCa remain undetected. This study aims to understand the pathological and molecular basis for csPCa visibility at mpMRI.  \nMethods: We performed a retrospective matched‐pair cohort study, including patients undergoing radical prostatectomy (RP) for csPCa (i.e., ISUP grade group ≥ 2) from 2015 to 2020, in our tertiary‐referral center. We screened for inclusion in the“mpMRI‐invisible” cohort all consecutive men (N = 45) having a negative preoperative mpMRI. The “mpMRI‐visible” cohort was matched based on age, PSA, prostate volume, ISUP grade group. Included patients underwent radiological and pathological open‐label revisions and characterization of the tumor mRNA expression profile (analyzing 780 gene transcripts, signaling pathways, and cell‐type profiling) . We compared the clinical‐pathological variables and the gene expression profile between matched pairs. The analysis was stratified according to histological characteristics and lesion diameter.  \nResults: We included 34 patients (17 per cohort); mean age at RP and PSA were 70.5 years (standard deviation [SD] = 7.7), 7.1 ng/mL (SD = 3.3), respectively; 65% of men were ISUP 2 . Overall, no significant differences in histopathological features, tumor diameter and location, mRNA profile, pathways, and cell‐type scores emerged between cohorts. In the stratified analysis, an upregulation of cell adhesion and motility, of extracellular matrix remodeling and of metastatic process pathways was present in specific subgroups of mpMRI‐invisible cancers.  \nConclusions: No PCa pathological or gene‐expression hallmarks explaining mp‐MRI invisibility were identified. Aggressive features can be present both in mpMRI‐invisible and ‐visible tumors.  \nThis is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.  \n© 2024 The Author(s) . The Prostate published by Wiley Periodicals LLC.  \nThe Prostate, 2025; 85:374–384 374 of 409  \n[https://doi.org/10.1002/pros.24838](https://doi.org/10.1002/pros.24838)  \n1 | Introduction  \nIn the last years, multiparametric magnetic resonance imaging (mpMRI) has become a key element in the diagnosis and staging of prostate cancer (PCa) [1] . Several randomized, controlled trials have demonstrated that mpMRI‐targeted biopsies increase the detection of high‐grade PCa while decreasing that of low‐grade tumors, considered as clinically insignificant. Using mpMRI as","cbCairtdGTpJJZ9s","https://ap.wps.com/l/cbCairtdGTpJJZ9s","pdf",2944349,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What problem does this study address regarding mpMRI in prostate cancer?\",\"answer\":\"Some clinically significant prostate cancers remain invisible on multiparametric MRI despite good performance. The study examines why these mpMRI-invisible cancers can be missed.\"},{\"question\":\"How were patients selected and compared in this matched-pair analysis?\",\"answer\":\"Men with clinically significant prostate cancer undergoing radical prostatectomy (ISUP grade group ≥ 2) from 2015 to 2020 were included. A cohort with negative preoperative mpMRI was matched to an mpMRI-visible cohort based on age, PSA, prostate volume, and ISUP grade group.\"},{\"question\":\"What were the main findings about histopathology and gene-expression profiles?\",\"answer\":\"Overall, no significant differences in histopathologic features, tumor diameter and location, mRNA expression profile, pathways, or cell-type scores were found between matched cohorts. In stratified analyses, specific subgroups of mpMRI-invisible cancers showed upregulation of cell adhesion, motility, extracellular matrix remodeling, and metastatic-process pathways.\"}]","Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging‐Invisible Prostate Cancers - A Matched-Pair Analysis | PDF",1790012255,28]